{
  "meta": {
    "title": "Pharmacology_Mini_Test_1_Basics_Ans",
    "url": "https://brainandscalpel.vercel.app/pharmacology-mini-test-1-basics-ans-58637cf7.html",
    "scrapedAt": "2025-11-30T07:33:16.466Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">40 mg</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">80 mg</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">160 mg</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">320 mg</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">What dose of a drug should be injected intravenously every 8 hours to obtain an average steady-state plasma drug concentration of 5 mg/L if the drug's volume of distribution is 30 L and its clearance is 8 L/hr?</span></p>",
      "unique_key": "Q237921",
      "question_audio": null,
      "question_video": null,
      "map_id": 237921,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000005
      ],
      "solution": "<ul><li>A maintenance dose of <strong>320 mg should be administered at 8 hour intervals to achieve the desired target concentration of 5 mg/L.</strong></li></ul><p>The corresponding formula needed for calculation requires the following values:</p><p><strong>Cp = target plasma concentration at steady state (mg/L)</strong></p><p><strong>Cl = clearance (L/h)</strong></p><p><strong>T = dosing interval (hours)</strong></p><p><strong>F = bioavailability</strong></p><p><strong>Maintenance dose = (Cp * Cl * T)/F</strong></p><p><strong>&rarr; (5*8*8)/1</strong></p><p><strong>= 320/1</strong></p><p><strong>= 320 </strong></p><ul><li>The dose required to establish a target plasma drug concentration is calculated by multiplying the clearance by the target concentration and dosage interval.</li><li>In this case, it is 5 mg/L *8 L/hr *8 hr = 320 mg.</li></ul><p><strong><em><u>Steady State</u></em></strong></p><ul><li>If fixed dose of a drug is administered after regular intervals, its plasma concentration starts increasing.</li><li>However, as plasma concentration rises, rate of elimination also starts increasing. When rate of administration becomes equal to rate of elimination, plasma concentration stabilizes. This is called steady state.</li><li><strong>Time to reach steady state depends on t&frac12;. It takes approximately 5 half lives.</strong></li><li><u>Steady state plasma concentration achieved depends on dose rate.</u></li><li><u>Variation between peak and trough concentration at steady state depends on dosing interval.</u> However, average steady state plasma concentration remains same irrespective of dosing interval provided dose rate remains same.</li></ul><p><strong><u>Key Takeaway</u></strong></p><p><strong>Steady State</strong></p><ul><li>If fixed dose of a drug is administered after regular intervals, its plasma Concentration starts increasing.</li><li>However, as plasma concentration rises, rate of elimination also starts increasing. <strong>When rate of administration becomes equal to rate of elimination, plasma concentration stabilizes. This is called steady state</strong>.</li></ul><p><strong>Must Know]</strong></p><p><strong>[Steady-state plasma concentration]</strong></p><p><strong>Reference:</strong> Essentials of Medical Pharmacology by KD Tripathi, 8<sup>th</sup> edition, page number. 40</p>",
      "correct_choice_id": 4,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">Irritation to the gastric mucosa with nausea and vomiting</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">Destruction of the drug by gastric acid or digestive enzymes</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">Formation of non-absorbable drug-food complexes</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">Variability in absorption caused by fluctuations in gastric emptying time</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is unlikely to be associated with oral drug administration of an enteric-coated dosage form?</span></p>",
      "unique_key": "Q237922",
      "question_audio": null,
      "question_video": null,
      "map_id": 237922,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000005
      ],
      "solution": "<ul><li><strong>Enteric coated tablets (having acid resistant coating)</strong> and sustained release preparations (drug particles coated with slowly dissolving material) can be used to overcome following problems:<ul><li><strong>Acid lability,</strong></li><li><strong>Gastric irritancy</strong></li><li><strong>Brief duration of action.</strong></li></ul></li><li><strong>Enteric coated tablet</strong> - the tablet is coated with a material that does not dissolve in the acidic medium of the stomach; the tablet disintegrates only on reaching the duodenum.(Option C ruled out)</li><li><u>Tasteless enteric-coated tablets and capsules are formulated to resist the acidic pH found in the stomach(Option B ruled out)</u></li><li>Once the preparation has passed into the intestine, the coating dissolves in the alkaline milieu and releases the drug.</li><li>Therefore, <u>gastric irritation, drug destruction by gastric acid, and the forming of complexes of the drug with food constituents will be avoided</u>(Option A ruled out)</li></ul><p><strong><u>Key Takeaway</u></strong></p><ul><li><strong>Enteric coated tablets can be used to overcome acid lability, gastric irritancy and brief duration of action.</strong></li></ul><p><strong>[Good to Know]</strong></p><p><strong>[Enteric-coated dosage form]</strong></p><p><strong>Reference:</strong> Essentials of Medical Pharmacology by KD Tripathi, 8<sup>th</sup> edition, page number 21</p>",
      "correct_choice_id": 14,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">CYP 1A2</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">CYP 2E1</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">CYP 2C9</span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">CYP 2D6</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 45 year old female patient brought to psychiatric OPD with history of depression along with bipolar disorder was put on anti-depressants by his psychiatrist to control her symptoms. She was also taking several other medicines along with standard therapy. Which of the following mitochondrial (Cytochrome) enzyme involved in the metabolism of Sertraline?</span></p>",
      "unique_key": "Q237923",
      "question_audio": null,
      "question_video": null,
      "map_id": 237923,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000005
      ],
      "solution": "<ul><li>Metabolism may occur with the help of <strong>microsomal</strong> (present in smooth endoplasmic reticulum) or <strong>non-microsomal</strong> enzymes.</li><li><u>Microsomal enzymes (monooxygenases, cytochrome P450 and glucuronyl transferase) may be</u> <strong><u>induced </u></strong>or <strong><u>inhibited</u></strong> <u>by other drugs whereas non-microsomal enzymes are not subjected to these interactions.</u></li><li><u>The drug which is metabolized by a microsomal enzyme is known as substrate and the chemical increasing or decreasing the number of enzymes is known as inducer or inhibitor respectively</u>.</li><li><strong>Enzyme inducers</strong> will <u>increase the metabolism of other drugs and thus their effect will decrease.</u></li><li><u>Therefore dose of such drugs (which are metabolized by microsomal enzymes) should be increased when administered along with microsomal enzyme inducers.</u></li><li><strong>Enzyme inhibitors</strong> will decrease the metabolism of drugs metabolized by microsomal enzymes, thus <strong>predisposes to the toxicity</strong> by such agents.</li><li><strong>CYP2D6</strong> This is the next most important CYP isoform after <strong>CYP3A4</strong> which metabolizes nearly 20% drugs including <strong>tricyclic antidepressants, selective serotonin reuptake inhibitors, many neuroleptics, antiarrhythmics, codeine, debrisoquine, metoprolol</strong>.</li></ul><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d10ehao5y6v0v4.cloudfront.net/V3/LBNEETPG/QuizNov2024/PharmacoMiniI26112024/3E.jpg\"><p><strong><u>Key Takeaway</u></strong></p><ul><li><strong>The drug which is metabolized by a microsomal enzyme is known as substrate and the chemical increasing or decreasing the number of enzymes is known as inducer or inhibitor respectively.</strong></li></ul><p><strong>[Must Know]</strong></p><p><strong>[Cytochrome enzyme]</strong></p><p><strong>Reference:</strong> Essentials of Medical Pharmacology by KD Tripathi, 8<sup>th</sup> edition, page number 29</p>",
      "correct_choice_id": 24,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">12 hours</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">24 hours</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">48 hours</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">72 hours</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 45 year old male with history of having opioid addiction brought to emergency department with an overdose of an opioid analgesic. On laboratory investigation the plasma concentration of the opioid compound found to be 32 mg/L. How long will it take to reach a safe plasma concentration of 2 mg/L if the drug's half-life is 6 hours?</span></p>",
      "unique_key": "Q237924",
      "question_audio": null,
      "question_video": null,
      "map_id": 237924,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000005
      ],
      "solution": "<ul><li><u>The half-life is the time required to reduce the plasma drug concentration 50%.</u></li><li><u>In this case, it will take four drug half-lives, or 24 hours, to reduce the plasma level from 32 to 2 mg/L.</u></li></ul><p><strong><u>Half Life (t<sub>1/2</sub>)</u></strong></p><ul><li>It is the time required to reduce the plasma concentration to half (50%) of the original value. If metabolism is more, half life is less and vice-versa.</li><li>It is a secondary pharmacokinetic parameter derived from two primary parameter; Vd and CL.</li><li><strong>It determines the dosing interval and time required to reach the steady state (It does not affect the dose of the drug).</strong></li><li>Drugs having short half lives are administered more frequently than those having longer half life.</li><li>It takes <strong>4 to 5 half lives for a drug to reach its steady state.</strong></li><li>t<sub>1/2</sub> = 0.693 &times; Vd / CL</li><li>Elimination of the drug from plasma is 50% in one half life, 75% (50 + 25) in two half lives, 87.5% (50 + 25 + 12.5) in three half lives and so on.</li></ul><p><strong><u>Key Takeaway</u></strong></p><ul><li><strong>It is the time required to reduce the plasma concentration to half (50%) of the original value.</strong></li></ul><p><strong>[Must Know]</strong></p><p><strong>[Half-life]</strong></p><p><strong>Reference:</strong> Essentials of Medical Pharmacology by KD Tripathi, 8<sup>th </sup>edition, page number 39</p>",
      "correct_choice_id": 32,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">The drug binds to the histamine receptor and partially activates it.</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">The drug binds to the histamine receptor but does not activate it.</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">The drug binds to the receptor, but not where histamine binds and prevents the receptor from being activated.</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">The drug irreversibly binds to the histamine receptor and renders it ineffective.</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A laboratory experiment is being conducted in a clinical pharmacology department in which a mammal is injected with a non-competitive antagonist to the histamine receptor. Which of the following best describes this agent?</span></p>",
      "unique_key": "Q237925",
      "question_audio": null,
      "question_video": null,
      "map_id": 237925,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000005
      ],
      "solution": "<ul><li><u>A noncompetitive antagonist binds to the receptor at a site other than the agonist-binding site and renders it less effective by preventing agonist binding or preventing activation.</u></li></ul><p><strong><u>Noncompetitive antagonism</u></strong></p><ul><li>The antagonist is <strong>chemically unrelated to the agonist</strong>, binds to a <strong>different allosteric site altering the receptor</strong> in such a way that it is unable to combine with the agonist or is unable to transduce the response.</li><li>This is also called <strong>allosteric antagonism</strong>. <u>Because the agonist and the antagonist are combining with different sites, there is no competition</u> between them-even high agonist concentration is unable to reverse the block completely.</li><li><strong>Increasing concentrations of the antagonist progressively flatten the agonist DRC</strong></li></ul><p><strong><u>Competitive antagonism</u></strong></p><ul><li>The antagonist is <strong>chemically similar to the agonist, competes with it</strong> and binds to the <strong>same site</strong> of the agonist molecules.</li><li>Because the <strong>antagonist has affinity but no intrinsic activity</strong>, no response is produced and the <strong>log DRC of the agonist is shifted to the right</strong>.</li></ul><p><strong><u>Key Takeaway</u></strong></p><ul><li><strong>A non-competitive antagonist binds to the receptor at a site other than the agonist-binding site and renders it less effective by preventing agonist binding or preventing activation</strong></li></ul><p><strong>[Must Know]</strong></p><p><strong>[Non-competitive antagonist]</strong></p><p><strong>Reference:</strong> Essentials of Medical Pharmacology by KD Tripathi, 8<sup>th</sup> edition, page number 68-69</p>",
      "correct_choice_id": 43,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">The drug's serum levels will likely need to be carefully monitored.</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">The drug is likely to cross the blood-brain barrier.</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">The drug is likely to have extensive drug-drug interactions.</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">The drug is unlikely to have any serious adverse effects at therapeutic dose</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 25 year old medical student was brought to medicine department with history of having acute bronchial asthma. He was also taking multiple medications for other disorders. Hence his physician has prescribed him a medicine with high therapeutic index. Which of the following statement best characterizes the drug with respect to its therapeutic index?</span></p>",
      "unique_key": "Q237926",
      "question_audio": null,
      "question_video": null,
      "map_id": 237926,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000005
      ],
      "solution": "<ul><li>An agent with a high therapeutic index means the toxic dose is very much higher than the therapeutic dose and it is less likely to produce toxic effects at therapeutic levels.</li><li>The gap between the therapeutic effect DRC and the adverse effect DRC defines the safety margin or the therapeutic index of a drug.</li></ul><p>In experimental animals, therapeutic index is often calculated as:</p><ul><li><strong>Therapeutic index = median lethal dose/median effective dose</strong></li><li><strong>'Therapeutic window' is bounded by the dose which produces <u>minimal therapeutic effect and the dose which produces maximal acceptable adverse effect and hence plasma levels needs to be monitored(Option A ruled out)</u></strong></li><li><strong>Option B, C is not related to the concept of therapeutic index.</strong></li></ul><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d10ehao5y6v0v4.cloudfront.net/V3/LBNEETPG/QuizNov2024/PharmacoMiniI26112024/6E.jpg\"><p><strong><u>Key Takeaway</u></strong></p><ul><li><strong>An agent with a high therapeutic index means the toxic dose is very much higher than the therapeutic dose and it is less likely to produce toxic effects at therapeutic levels.</strong></li></ul><p><strong>[Must Know]</strong></p><p><strong>[Therapeutic index]</strong></p><p><strong>Reference:</strong> Essentials of Medical Pharmacology by KD Tripathi, 8<sup>th</sup> edition, page number 65-66</p>",
      "correct_choice_id": 54,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">Post marketing surveillance</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">Phase II Randomized control trial (RCT)</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">Phase I trial</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">Phase III Randomized control trial (RCT)</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following study design of a clinical trial aims to assess the maximum tolerable dose of a new drug?</span></p>",
      "unique_key": "Q237927",
      "question_audio": null,
      "question_video": null,
      "map_id": 237927,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000005
      ],
      "solution": "<p><strong><u>Phase 1 Clinical trial</u></strong></p><ul><li>Here, the drug is tested in <strong>normal human volunteers</strong> (extremes of ages; elderly and children are excluded).</li><li>As the drug is not tested in the patients, so we cannot determine efficacy in this phase. This is <strong>mainly for toxicity and pharmacokinetic studies</strong>.</li><li>This is <strong>first in human study.</strong></li><li>The idea of testing the new drug in normal humans is based on the fact that <strong>healthy persons are more likely to tolerate the adverse effects of the drug than diseased persons.</strong></li><li>Because anti-cancer drugs can produce unacceptable toxicity and we cannot expose healthy humans to such a toxicity, the phase-1 trials for anticancer drugs are done in the patients.</li></ul><p><strong><u>Summary of Clinical trials</u></strong></p><img class=\"w-100\" style=\"height: auto; display: block; vertical-align: middle; border: 0;\" src=\"https://d10ehao5y6v0v4.cloudfront.net/V3/LBNEETPG/QuizNov2024/PharmacoMiniI26112024/7E.jpg\"><p><strong><u>Key Takeaway</u></strong></p><ul><li><strong>Phase I trial is done on healthy volunteers mainly to know safety, tolerability o drugs with maximum tolerable dose.</strong></li></ul><p><strong>[Must Know]</strong></p><p><strong>[Phase I trial]</strong></p><p><strong>Reference:</strong> Essentials of Medical Pharmacology by KD Tripathi, 8<sup>th</sup> edition, page number:90</p>",
      "correct_choice_id": 63,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">Muscarine-containing mushrooms</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">Nicotine-containing insecticide</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">Organophosphate-containing insecticide</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">Atropine-containing mushrooms</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 41 year old man was brought to the emergency department because of severe vomiting and diarrhoea that started just after a meal. The patient presented with profuse salivation, lacrimation and wheezing. His skin was moist and his pupils were miotic. Skeletal muscle movements were normal. Blood pressure was 80/50 mm Hg, pulse 46 bpm. Which of the following compound is responsible for development of poisoning of this patient?</span></p>",
      "unique_key": "Q237928",
      "question_audio": null,
      "question_video": null,
      "map_id": 237928,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000005
      ],
      "solution": "<ul><li>The patient's signs and symptoms are consistent with the diagnosis of muscarine poisoning.</li><li>High concentrations of muscarine are present in various species of Inocybe and Clitocybe</li><li>The symptoms of muscarine intoxication start within 1 hour after the ingestion and are all attributable to activation of muscarinic receptors.</li></ul><p><strong><u>Muscarine type (Early mushroom poisoning) due to Inocybe and related species.</u></strong></p><ul><li>Symptoms characteristic of muscarinic actions appear within an hour of eating the mushroom, and are promptly reversed by atropine.</li></ul><p><strong><u>Hallucinogenic type</u></strong></p><ul><li>It is due to muscimol and other isoxazole compounds which are present in Muscaria and related mushrooms in much larger quantities than is muscarine.</li><li>These compounds activate amino acid receptors, and block muscarinic receptors in the brain; have hallucinogenic property.</li></ul><p><strong><u>Phalloidin type (Late mushroom poisoning)</u></strong></p><ul><li>It is due to peptide toxins found in phalloides, Galerina and related species.</li><li>The symptoms start after many hours and are due to damage to the gastrointestinal mucosa, liver and kidney.</li></ul><p><strong>Option B</strong>: Nicotine poisoning results activation of N<sub>N</sub> receptors in ganglia and adrenal medulla causing cold sweat, rapid and irregular pulse and hypertension, followed by hypotension and collapse.</p><p>Moreover, the activation of N<sub>M</sub> receptors at the motor end plate would cause muscle paralysis due to depolarization blockade, which is absent in this patient.</p><p><strong>Option C:</strong> Poisoning by organophosphates causes symptoms due to activation of muscarinic receptors; in addition, there are symptoms due to activation of nicotinic receptors (i.e., skeletal muscle paralysis due to depolarization blockade).</p><p><strong>Option D:</strong> The symptoms of atropine poisoning are due to blockade of muscarinic receptors</p><p><strong><u>Key Takeaway:</u></strong></p><ul><li><strong>Muscarine type (Early mushroom poisoning) due to Inocybe and related species. Symptoms characteristic of muscarinic actions appear within an hour of eating the mushroom and are promptly reversed by atropine.</strong></li></ul><p><strong>[Good to Know]</strong></p><p><strong>[Muscarine poisoning]</strong></p><p><strong>Reference:</strong> Essentials of Medical Pharmacology by KD Tripathi, 8<sup>th </sup>edition, page number. 115-116</p>",
      "correct_choice_id": 71,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">Mydriasis</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">Constipation</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">Overflow incontinence</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">Sialorrhea</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 64 year old man with recently diagnosed myasthenia gravis brought to endocrinologist for further medical assistance. He was later started with neostigmine. Which of the following adverse effects would most likely be seen in this patient due to neostigmine?</span></p>",
      "unique_key": "Q237929",
      "question_audio": null,
      "question_video": null,
      "map_id": 237929,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000005
      ],
      "solution": "<ul><li>Neostigmine is a cholinesterase inhibitor and therefore increases the availability of acetylcholine at all cholinergic synapses, eliciting muscarinic effects, mainly in the gastrointestinal tract.</li><li>These drugs act by inhibiting the enzyme acetylcholinesterase, thus increasing the availability and prolonging the action of ACh.</li><li><strong>Neostigmine</strong> is preferred for the <strong>treatment of myasthenia gravis.</strong></li><li>It does not produce adverse effects in the CNS (does not cross BBB) and it also has direct NM receptor agonistic action.</li><li>It can also be used for the <u>treatment of cobra bite (cobra venom contain the compounds that cause skeletal muscle paralysis), post operative paralytic ileus, atony of urinary bladder and the reversal of competitive skeletal muscle relaxants.</u></li><li><strong><u>Eye:</u></strong> Cholinergic system stimulates sphincter pupillae (circular muscle of eye) and thus results in miosis (M3).</li><li><strong><u>Glands</u>:</strong> Cholinergic system <strong>stimulates the secretion of glands and results in the increased salivation, lacrimation as well as sweating (M3).</strong></li><li><strong><u>Urinary bladder</u>:</strong> Cholinergic drugs stimulate detrusor and relax the trigone (sphincter) of urinary bladder resulting in increased micturition (M3).</li><li><strong><u>Gastrointestinal tract</u>:</strong> Hydrochloric acid secretion in the stomach (M1 and M3) is stimulated by parasympathetic system and thus increases the risk of peptic ulcer disease.</li></ul><p><strong>Option A, B &amp; C:</strong> By increasing acetylcholine availability, neostigmine causes effects opposite to those given in above options.</p><p>All these effects can occur because of atropinic side effects.</p><p><strong><u>Key Takeaway</u></strong></p><ul><li><strong>Neostigmine is a cholinesterase inhibitor and therefore increases the availability of acetylcholine at all cholinergic synapses, eliciting muscarinic effects, mainly in the gastrointestinal tract.</strong></li></ul><p><strong>[Must Know]</strong></p><p><strong>[Neostigmine]</strong></p><p><strong>Reference:</strong> Essentials of Medical Pharmacology by KD Tripathi, 8<sup>th</sup> edition, page number 118-119</p>",
      "correct_choice_id": 84,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">Neostigmine</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">Albuterol</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">Physostigmine</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">Epinephrine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 5 year old boy was brought to the emergency department with mental confusion, restlessness, incoherence, and hallucinatory behaviour after inadvertently eating black berries of a wild plant. Physical examination revealed mydriasis; dry, hot and scarlet skin; and a distended abdomen with no bowel sounds. Vital signs were temperature 104 &deg;F, heart rate 150 bpm, blood pressure 100/60 mm Hg. Which of the following drugs would antagonize most of the symptoms exhibited by the patient?</span></p>",
      "unique_key": "Q237930",
      "question_audio": null,
      "question_video": null,
      "map_id": 237930,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000005
      ],
      "solution": "<ul><li><u>The patient's symptoms, signs, and history indicate that he was most likely poisoned by black berries (Atropa belladonna), a plant containing antimuscarinic alkaloids (mainly atropine and scopolamine).</u></li><li>Antimuscarinic syndrome is due to competitive blockade of muscarinic receptors all over the body.</li><li><u>Physostigmine is an anticholinesterase inhibitor that can cross the blood-brain barrier, increasing the availability of acetylcholine both in the central nervous system and in the periphery.</u></li></ul><p><strong><u>Belladonna poisoning</u></strong></p><ul><li><strong>It occurs due to drug overdose or consumption of seeds and berries of belladonna/datura plant. Children are highly susceptible.</strong></li></ul><p><strong><u>Manifestations are due to exaggerated pharmacological actions.</u></strong></p><ul><li>Dry mouth, difficulty in swallowing and talking.</li><li>Dry, flushed and hot skin (especially over face and neck), fever, difficulty in micturition, decreased bowel sounds.</li><li>A scarlet rash</li><li>Dilated pupil, photophobia, blurring of near vision, palpitation.</li><li>Excitement, psychotic behaviour, ataxia, delirium, dreadful visual hallucinations.</li><li>Hypotension, weak and rapid pulse, cardiovascular collapse with respiratory depression.</li><li>Convulsions and coma occur only in severe poisoning.</li></ul><p><strong><u>Diagnosis</u></strong></p><ul><li>Methacholine 5 mg or neostigmine 1 mg s.c. fails to induce typical muscarinic effects.</li></ul><p><strong><u>Treatment</u></strong></p><ul><li>If the poison has been ingested, gastric lavage should be done with tannic acid (KMnO4 is ineffective in oxidizing atropine).</li><li>The patient should be kept in a dark quiet room.</li><li>Cold sponging or ice bags are applied to reduce body temperature.</li><li><strong>Physostigmine 1-3 mg s.c. or i.v. antagonises both central and peripheral effects</strong>, but has been found to produce hypotension and arrhythmias in some cases.</li></ul><p><strong>Option A:</strong> Neostigmine, a quaternary ammonium compound, is a cholinesterase inhibitor that cannot cross the blood-brain barrier and therefore is unable to counteract the central effects of atropine and scopolamine.</p><p><strong>Option B &amp; D:</strong> These drugs are adrenergic system agonists and are therefore useless/even dangerous in anti-muscarinic poisoning.</p><p><strong><u>Key Takeaway</u></strong></p><ul><li><strong>Antimuscarinic syndrome by Atropa belladona is due to competitive blockade of muscarinic receptors all over the body.</strong></li><li><strong>Physostigmine is an anticholinesterase inhibitor that can cross the blood-brain barrier, increasing the availability of acetylcholine both in the central nervous system and in the periphery.</strong></li></ul><p><strong>[Must Know]</strong></p><p><strong>[Physostigmine]</strong></p><p><strong>Reference:</strong> Essentials of Medical Pharmacology by KD Tripathi, 8<sup>th</sup> edition, page number 132</p>",
      "correct_choice_id": 93,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">Physostigmine induced sweating</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">Epinephrine induced hypertension</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">Nicotine induced skin vasoconstriction</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">Glycopyrrolate induced bronchodilation</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Atropine was given intramuscularly to several dogs during a lab experiment. One hour later each dog received an intramuscular injection of an autonomic drug, and the effects of that drug were recorded. Which of the following expected drug-induced effects was most likely best antagonized by atropine pre-treatment?</span></p>",
      "unique_key": "Q237931",
      "question_audio": null,
      "question_video": null,
      "map_id": 237931,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000005
      ],
      "solution": "<ul><li><strong>Physostigmine is a cholinesterase inhibitor, and therefore it can increase the availability of acetylcholine</strong> at cholinergic neuroeffector junctions.</li><li><strong><u>Activation of M3 receptors in sweat glands promotes sweating</u></strong>.</li><li>By blocking M3 receptors, <strong>atropine can counteract this action</strong>.</li><li><strong>Physostigmine</strong> is naturally occurring tertiary amine and is lipid soluble.</li><li>Tacrine, donepezil, rivastigmine and galantamine are also lipid soluble drugs.</li><li><strong>All other</strong> reversible anti-cholinesterases are synthetic quaternary compounds and are lipid insoluble.</li><li><u>Due to high lipid solubility, physostigmine can be administered orally and it can cross blood brain</u> <u>barrier and corneal membrane</u>.</li><li><strong>Atropine is the specific antidote for anti ChE and early mushroom poisoning</strong></li><li><strong>Atropine or glycopyrrolate is also given to block muscarinic actions of neostigmine</strong> used for <u>myasthenia gravis, decurarization or cobra envenomation.</u></li></ul><p><strong>Option B:</strong> Epinephrine increase blood pressure by activating &alpha;1 and &beta;1 receptors. These receptors are not affected by atropine.</p><p><strong>Option C:</strong> Nicotine can cause skin vasoconstriction by activating Nn receptors in sympathetic ganglia. Atropine has negligible effects on Nn receptors.</p><p><strong>Option D:</strong> Glycopyrrolate induces bronchodilation by blocking M3 and Nn receptors. Atropine can block M3 receptors and therefore can increase, not counteract the action of glycopyrrolate.</p><p><strong><u>Key Takeaway</u></strong></p><ul><li><strong>Physostigmine is a cholinesterase inhibitor and therefore it can increase the availability of acetylcholine at cholinergic neuroeffector junctions. And activation of M3 receptors in sweat glands promotes sweating which is blocked by atropine pre-treatment</strong></li></ul><p><strong>[Must Know]</strong></p><p><strong>[Atropine]</strong></p><p><strong>Reference:</strong> Essentials of Medical Pharmacology by KD Tripathi, 8<sup>th</sup> edition, page number 132</p>",
      "correct_choice_id": 101,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">Dopamine</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">Norepinephrine</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">Isoproterenol</span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">Dobutamine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 60 year old man hospitalized following a myocardial infarction along with pronounced decrease in blood pressure and urine output on admission. A diagnosis of cardiogenic shock was made and an emergency therapy was started. A mixed acting adrenergic drug was given by intravenous infusion by attending physician. Which of the following drug would be the most appropriate for the patient?</span></p>",
      "unique_key": "Q237932",
      "question_audio": null,
      "question_video": null,
      "map_id": 237932,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000005
      ],
      "solution": "<ul><li><u>Dopamine is a mixed-acting adrenergic drug that can directly activate &alpha;, &beta;, and dopamine receptors.</u></li><li>It can also increase the release of norepinephrine from adrenergic terminals.</li><li><strong>Dopamine is the drug of choice for cardiogenic shock with oliguric renal failure.</strong></li></ul><p><strong><u>Dopamine (DA)</u></strong></p><ul><li><strong>It is a dopaminergic (D1 and D2) as well as weaker adrenergic &beta;1 (but not &beta;2) + very weak &alpha; receptor agonist.</strong></li><li><u>The D1 receptors in renal and mesenteric blood vessels are the most sensitive: i.v. infusion of low dose of DA dilates these vessels (by raising intracellular cAMP).</u></li><li><u>This increases g.f.r. In addition DA exerts natriuretic effect by D1 receptors on proximal tubular cells.</u></li><li>Moderately higher doses produce a positive inotropic (direct &beta;1 and D1 action + that due to NA release), but little chronotropic effect on heart.</li><li>Vasoconstriction (&alpha;1 action) occurs only when large doses are infused. At doses normally employed, it raises cardiac output and systolic BP with little effect on diastolic BP.</li><li><strong>Dopamine is used in patients of cardiogenic or septic shock and acute heart failure wherein it increases BP and urine outflow.</strong></li><li>It is administered by i.v. infusion (0.2-1 mg/min) which is regulated by monitoring BP and rate of urine formation.</li></ul><p><strong><u>Dose dependant actions of Dopamine</u></strong></p><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d10ehao5y6v0v4.cloudfront.net/V3/LBNEETPG/QuizNov2024/PharmacoMiniI26112024/12E.jpg\"><p><strong>Option B, C &amp; D:</strong> All of these drugs are adrenergic agonists (i.e., direct acting adrenergic agents).</p><p><strong><u>Key Takeaway</u></strong></p><ul><li><strong>Dopamine is the drug of choice for cardiogenic shock with oliguric renal failure. It acts on D1 (at a dose of 1-2 >mg/kg/min.) It causes renal vasodilation by acting on D1 receptors and maintains renal perfusion and GFR.</strong></li></ul><p><strong>[Must Know]</strong></p><p><strong>[Dopamine]</strong></p><p><strong>Reference:</strong> Essentials of Medical Pharmacology by KD Tripathi, 8<sup>th</sup> edition, page number 146</p>",
      "correct_choice_id": 111,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">Atenolol</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">Metoprolol</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">Propranolol</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">Esmolol</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following Beta-adrenoceptor blocking agent's dose must be adjusted/reduced in patients having renal impairment with Creatinine clearance less than of 30 mL/min?</span></p>",
      "unique_key": "Q237933",
      "question_audio": null,
      "question_video": null,
      "map_id": 237933,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000005
      ],
      "solution": "<p><strong><u>Atenolol</u></strong></p><ul><li>Atenolol is a &beta;1-selective antagonist that is devoid of intrinsic sympathomimetic and membrane-stabilizing activity.</li><li>Atenolol is very hydrophilic and appears to penetrate the CNS only to a limited extent.</li><li>It is <u>incompletely absorbed (~50%) and is excreted largely unchanged in the urine, with elimination t<sub>1/2</sub> of 5 to 8 h.</u></li><li><strong>The drug accumulates in patients with renal failure, and dosage should be adjusted for patients whose creatinine clearance is less than 35 mL/min.</strong></li></ul><p><strong><u>Features of Beta-adrenoceptor blocking agents with Low lipid solubility (atenolol, celiprolol, bisoprolol, sotalol)</u></strong></p><ol><li>They are <strong>less likely to produce sleep disturbances, nightmares, or to increase the incidence of mental depression</strong>.</li><li>They are incompletely absorbed orally, but <strong>do not undergo first pass metabolism and are primarily excreted unchanged in urine:</strong> are longer acting (t&frac12; 6-20 hours) and tend to be effective in a narrow dose range.</li></ol><p><strong>Option B, C &amp; D:</strong> All of these drugs don't have renal excretion, hence no dose adjustment is required.</p><p><strong><u>Key Takeaway</u></strong></p><ul><li><strong>Atenolol accumulates in patients with renal failure and dosage should be adjusted for patients whose creatinine clearance is less than 35 mL/min.</strong></li></ul><p><strong>[Good to Know]</strong></p><p><strong>[Atenolol]</strong></p><p><strong>Reference:</strong> Goodman &amp; Gilman's The Pharmacological Basis of therapeutics, 14<sup>th</sup> edition, page number: 281</p>",
      "correct_choice_id": 121,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">Calcium channel blockers</span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">Beta blockers</span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">Nitrates</span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">ACE inhibitors</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following anti-hypertensive agent is associated with maximum incidence of impotence?</span></p>",
      "unique_key": "Q237934",
      "question_audio": null,
      "question_video": null,
      "map_id": 237934,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000005
      ],
      "solution": "<ul><li><u>Vasodilation is required for erection of penis. Non-selective &beta;-blockers inhibit the &beta;2 mediated vasodilation and may result in erectile dysfunction and impotence.</u></li></ul><p><strong><u>Limitations of Non-selective &beta;-Blockers</u></strong></p><ul><li>Contraindicated in bronchial asthma due to their bronchoconstrictor action.</li><li>Hypoglycemia is commonly observed in diabetic patients receiving insulin and oral hypoglycemic drugs.</li><li>These drugs are therefore contraindicated in diabetic patients.</li><li>On long term use non selective &beta; blockers can adversely affect serum lipid profile and can cause glucose intolerance.</li><li>By causing vasoconstriction (&beta;2 is vasodilatory), these drugs can worsen peripheral vascular disease (contraindicated in Raynaud's disease).</li><li>These drugs can impair exercise capacity due to blockade of skeletal vascular &beta;2 receptors.</li><li><strong>Male patients more frequently complain of sexual distress.</strong></li></ul><p><strong><u>Drugs implicated in causation of erectile dysfunction are:</u></strong></p><ul><li>&beta;-blockers</li><li>Clonidine</li><li>&alpha;-methyldopa</li><li>Thiazides</li><li>Antipsychotics e.g. phenothiazines</li><li>MAO inhibitors</li><li>Benzodiazepines</li><li>Antiandrogens</li><li>Estrogens</li><li>Alcohol</li></ul><p><strong><u>Drugs used for the treatment of erectile dysfunction.</u></strong></p><ul><li>Phosphodiesterase inhbibitors (sildenafil, tadalafil and vardenafil)</li><li>&alpha;2 blockers (Yohimbine)</li><li>Non-selective &alpha; blockers (phentolamine)</li><li>Dopamine analog (apomorphine)</li><li>PGE1 analog (alprostadil)</li></ul><p><strong><u>Key Takeaway</u></strong></p><ul><li><strong>Non-selective &beta;-blockers inhibit the &beta;2 mediated vasodilation and may result in erectile dysfunction and impotence.</strong></li></ul><p><strong>[May Know]</strong></p><p><strong>[Beta blockers]</strong></p><p><strong>Reference:</strong> Essentials of Medical Pharmacology by KD Tripathi, 8<sup>th</sup> edition, page number:160-161</p>",
      "correct_choice_id": 132,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15,
      "choices": [
        {
          "id": 141,
          "text": "<p><span style=\"font-size:12.0pt;\">Inhibition of adenylyl cyclase</span></p>"
        },
        {
          "id": 142,
          "text": "<p><span style=\"font-size:12.0pt;\">Activation of adenylyl cyclase</span></p>"
        },
        {
          "id": 143,
          "text": "<p><span style=\"font-size:12.0pt;\">Activation of phospholipase C</span></p>"
        },
        {
          "id": 144,
          "text": "<p><span style=\"font-size:12.0pt;\">Inhibition of phospholipase C</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 45 year old woman came to ophthalmologist for follow up after cataract surgery. She was advised to lower intraocular pressure and prescribed an appropriate agent after cataract surgery. Which of the following mechanism would most likely lead to the desired effect?</span></p>",
      "unique_key": "Q237935",
      "question_audio": null,
      "question_video": null,
      "map_id": 237935,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1000005
      ],
      "solution": "<ul><li><strong>&alpha;2-adrenoceptor agonists such as apraclonidine are used for short-term control of intraocular pressure after cataract surgery.</strong></li><li><u>Activation of &alpha; 2-adrenoceptors is coupled with inhibition of adenylyl cyclase and decreased cAMP levels.</u></li><li><strong>Intraocular pressure</strong> can be decreased by a <strong>decreased production or by an increased outflow of aqueous humor.</strong></li><li>A <strong>decreased product ion can follow either the activation of &alpha;2 receptors or the blockade of &beta;2 receptors.</strong></li></ul><p><strong><u>Role of Adrenergic system on Aqueous humor dynamics</u></strong></p><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d10ehao5y6v0v4.cloudfront.net/V3/LBNEETPG/QuizNov2024/PharmacoMiniI26112024/15E.jpg\"><p><strong><u>Mode of actions for different anti-glaucoma drugs</u></strong></p><img class=\"w-100\" style=\"height:auto;display:block;vertical-align: middle;border:0; \"src=\"https://d10ehao5y6v0v4.cloudfront.net/V3/LBNEETPG/QuizNov2024/PharmacoMiniI26112024/15E1.jpg\"><p><strong><u>Key Takeaway:</u></strong></p><ul><li><strong>&alpha;2 - adrenoceptor agonists such as apraclonidine are used for short-term control of intraocular pressure after cataract surgery.</strong></li></ul><p><strong>[Good to Know]</strong></p><p><strong>[Apraclonidine]</strong></p><p><strong>Reference:</strong> Essentials of Medical Pharmacology by KD Tripathi, 8<sup>th </sup>edition, page number 168</p>",
      "correct_choice_id": 141,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}